Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and China, has entered into a lucrative licensing agreement with South Korea-based SK Biopharmaceuticals, granting the latter exclusive global rights to develop, manufacture, and commercialize the radiopharmaceutical FL-091. The deal is valued at USD 571.5 million and encompasses clinical study, development, manufacturing, and commercial rights to FL-091, which targets neurotensin receptor 1 (NTSR1) positive tumors .
FL-091 is a small-molecule radioactive ligand carrier that is designed to deliver radiation therapy drugs directly to cancer cells by binding specifically to NTSR1, a receptor overexpressed in several types of cancers, including colorectal and pancreatic. This innovative approach to cancer treatment has the potential to improve patient outcomes by increasing the precision of radiation delivery to tumor sites.
Under the terms of the agreement, Full-Life will receive an upfront payment, R&D and commercial milestone payments, and royalties on future global sales of FL-091. Additionally, SK Biopharmaceuticals will have priority negotiation rights for other radionuclide drug conjugate (RDC) programs in Full-Life’s portfolio, signaling a broader strategic partnership between the two companies.
This licensing deal is a significant milestone for Full-Life Technologies, as it marks the international recognition of their radiopharmaceutical development capabilities and underscores their commitment to bringing innovative cancer treatments to market. For SK Biopharmaceuticals, the agreement represents a strategic expansion into the radiopharmaceutical space, complementing their existing focus on central nervous system (CNS) and oncology treatments.
The agreement also highlights the growing interest and investment in radiopharmaceuticals, a sector that has seen increased dealmaking and development activity in recent years. As companies like Full-Life and SK Biopharmaceuticals continue to innovate in this space, there is a strong potential for the development of novel therapies that could transform cancer treatment and improve patient outcomes globally .- Flcube.com
